Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
649P An oral, chemo-free regimen (osimertinib plus anloti... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
649P An oral, chemo-free regimen (osimertinib plus anlotinib) as first-line treatment for EGFR-mutated advanced NSCLC (AUTOMAN): Safety and survival outcome
0
Authors
Bin Han
8 more
Bin Han
•
Bo Yan
6 more
•
Aiqin Gu
Published
December 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Annals of Oncology
Topics
Mathematics
Cancer Oncology
Medicine
Internal Medicine
Pulmonary And Respiratory Medicine
Show all topics
DOI
10.1016/j.annonc.2024.10.682
